Ophiomics is growing! We are very happy to have onboard new team members that bring expertise in strategic fields. Our team will be focused on developing HepatoPredict – A decision tool for Liver Transplantation based on molecular signature, that has recently been awarded funding by the program EIC Accelerator. Welcome!SaraDianaMariaAndréFilipa
We have moved to a new location at Lispolis (Lisbon’s Technological Park), a strategic location for technological and innovative companies in Lisbon. We have a new home at the Center of Incubation and Development with a dedicated office space and a custom-built and newly equipped laboratory. You can find us at:
As part of its development of new diagnostic and prognostic solutions for liver cancer, Ophiomics conducts research using data from patients, and conducts retrospective and prospective clinical studies. These all raise multiple ethics issues. We are happy to announce that Prof. Ana Sofia Carvalho is joining our Advisory Board as our Ethics Mentor. Prof. Carvalho
Ophiomics wins EIC accelerator funding in its pilot scheme. This hybrid funding scheme that includes a grant together with investment from the European Investment Bank, will permit Ophiomics to take HepatoPredcit to market and make a difference in selecting the right patients cancer for liver transplantation.
Health Europa, a publisher of digital content on Health issue sin Europe and beyond, published a feature about Ophiomics and HepatoPredict in its Health Europa Quarterly Issue.
Ophiomics was granted the SME Instrument Phase I grant to conduct a Feasibility study for its HepatoPredict genomic signature for Liver Cancer. Check here for the CORDIS page. This grant will permit Ophiomics to build a business case for HepatoPredict.